Chemomab Therapeutics (CMMB) Prezzo delle Azioni, Quotazione, Notizie e Storico | Benzinga

Chemomab Therapeutics Ltd (CMMB) Prezzo delle Azioni, Quotazione, Notizie e Storico

CMMBNASDAQ

Trade with Public

Trade with Public

$1.17

-0.095-7.51%

Ult. Agg.: Oct 19, 4:08 PM

$1.19

-0.075-5.93%

PanoramicaNotizie Previsioni utili Eventi Obiettivi di prezzo Dati finanziari Sentiment Azionariato Confronta Rapporto azionario

© 2026 Benzinga | All Rights Reserved

Statistiche Chiave

Aperto

$1.25

Chiuso

$1.17

Volume / Media

36.48K / 103.44K

Intervallo giornaliero

$1.17 - $1.26

Intervallo a 52 settimane

1.05 - 3.50

Capitalizzazione di mercato

$8.72M

Rapporto P/E

-

Rendimento del dividendo

-

Exchange

NASDAQ

RSI

28

Vendite allo scoperto

0.15%

Periodo di copertura

1

Notizie Recenti di Chemomab Therapeutics Ltd

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.

Vandana Singh

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Avi Kapoor

Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise

Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver stiffness and pruritis, with a favorable safety profile.

Vandana Singh

What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

Vandana Singh

Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion.

Avi Kapoor

Dati finanziari

Trimestrale

Annuale

Nome

Ricavi Variazioni
Lordo Variazioni
EBITDA Variazioni
EBIT Variazioni
Utili Variazioni

Flussi di Cassa

Flusso di Cassa Operativo (TTM)

-8.73M

Flusso di Cassa da Investimenti (TTM)

3.22M

Flusso di Cassa da Finanziamenti (TTM)

5.91M

Flusso di Cassa Libero (TTM)

-8.74M

Spese in Conto Capitale (TTM)

-

Variazione Netta della Cassa (TTM)

403.00K

Valutazione degli analisti

4.2

Acquistare

Acquistare fortemente

Acquistare

Tenere

Vendere

Vendere fortemente

Metriche di Valutazione

Valore Aziendale

-$1.10M

Rapporto P/E (TTM)

-

Rapporto P/E (FWD)

-

Rapporto PEG (TTM)

-

Rapporto P/S (TTM)

-

Rapporto P/B (TTM)

1.07

Rendimento da Utili % (TTM)

-75.89%

Rendimento da Utili % (FWD)

-

EV / EBITDA (TTM)

-

Prezzo / EBITDA (TTM)

-

Prezzo / Flusso di Cassa Libero (TTM)

-

Valore Contable / Azione

$1.19

Debito Aziendale

Debito Totale

-

Debito a Lungo Termine

-

Emissione di Debito a Lungo Termine (TTM)

-

Rimborso del Debito a Lungo Termine (TTM)

-

Cassa Totale

$6.00M

Rapporto Debito / Capitale

-

Emissione di Debito (TTM)

-

Rimborso del Debito (TTM)

-